Pre-earnings options volume in MannKind is 1.5x normal with calls leading puts 19:2. Implied volatility suggests the market is anticipating a move near 10.8%, or 41c, after results are released. Median move over the past eight quarters is 4.4%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MNKD:
- Is MNKD a Buy, Before Earnings?
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
- MannKind says INHALE-1 study now fully enrolled
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million